Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Account Payables (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Change in Account Payables for 6 consecutive years, with -$2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 11.44% year-over-year to -$2.2 million, compared with a TTM value of -$999000.0 through Sep 2025, down 166.91%, and an annual FY2024 reading of -$512000.0, down 129.26% over the prior year.
  • Change in Account Payables was -$2.2 million for Q3 2025 at Ovid Therapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.5 million in Q4 2023 and bottomed at -$4.9 million in Q1 2022.
  • Average Change in Account Payables over 5 years is -$413069.9, with a median of -$121000.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables skyrocketed 718.54% in 2022, then plummeted 1060.75% in 2025.
  • Year by year, Change in Account Payables stood at -$148713.0 in 2021, then skyrocketed by 718.54% to $919844.0 in 2022, then surged by 170.26% to $2.5 million in 2023, then crashed by 80.65% to $481000.0 in 2024, then crashed by 565.7% to -$2.2 million in 2025.
  • Business Quant data shows Change in Account Payables for OVID at -$2.2 million in Q3 2025, $2.0 million in Q2 2025, and -$1.2 million in Q1 2025.